Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Bevacizumab. Found 10 abstracts

Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). The oncologist. 2019 Dec 18;.
Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS. Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Gynecol Oncol. 2019 Aug;154(2):420-5.
Wagner J, Kline CL, Zhou L, Khazak V, El-Deiry WS. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. Journal of experimental & clinical cancer research : CR. 2018 Jan 22;37(1):11.   PMCID: PMC5778752
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-91.   PMCID: PMC5715461
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. The New England journal of medicine. 2016 Feb 25;374(8):738-48.   PMCID: PMC5081077
Abbosh PH, McConkey DJ, Plimack ER. Targeting Signaling Transduction Pathways in Bladder Cancer. Current oncology reports. 2015 Dec;17(12):58.
Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study. Gynecol Oncol. 2015 Oct;139(1):17-22.   PMCID: 4600605
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology. 2012 Mar;124(3):563-8.   PMCID: PMC3278517
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology. 2011 Apr;121(1):230-8.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Bevacizumab

Bevacizumab Paclitaxel administration & dosage Middle Aged Antineoplastic Combined Chemotherapy Protocols Carboplatin Female Disease-Free Survival Ovarian cancer adverse effects drug therapy Ovarian Neoplasms therapeutic use Aged Axitinib phase-ii trial pathology Neoplasm Staging Clear cell Pten Survival Rate mortality axitinib cell Pik3ca Non-Small-Cell Lung Carcinoma CA-125 Cancer therapy Rectal cancer Proportional Hazards Models Everolimus independent prognostic-factor Survival outcomes Pazopanib Young Adult chemotherapy Anti-angiogenic therapy Drug Administration Schedule therapy guidelines Imidazoles solid Treatment Outcome progression ca 125 Erbb3 adverse induction chemotherapy platinum-resistant Gog Indazoles triple angiokinase inhibitor Erbb2 survival half-life tumors Male NRG Oncology article Front-line therapy effects Avastin non-squamous epithelial ovarian imatinib mesylate Copy number abnormality Kaplan-Meier Estimate Intravenous Infusions Response assessment Neutropenia non-small-cell lung cancer bevacizumab gynecologic-oncology-group carcinoma Cytoreduction Surgical Procedures ca125 response criteria mTOR Lung Neoplasms lung-cancer Dovitinib Mutation Adjuvant therapy chemically induced Sunitinib Phase II trial Antiangiogenesis Intention to Treat Analysis Pharmacogenomics Advanced epithelial ovarian cancer Cetuximab inhibitors Adult Egfr Body mass index Monoclonal Antibodies-Humanized fibroblast-growth-factor Racial differences Chemotherapy 80 and over Aged Glandular and Epithelial Neoplasms Bladder cancer Fgfr3 endothelial-cells Tyrosine kinase Onc201 Peritoneal Neoplasms Erlotinib Local Neoplasm Recurrence tyrosine kinase inhibitor Fallopian Tube Neoplasms
Last updated on Saturday, July 04, 2020